Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis In-Licenses China Rights to an HCV Treatment from Medivir

publication date: Aug 18, 2017

Ascletis of Hangzhou has in-licensed a third HCV treatment. Its latest acquisition is a nucleotide polymerase inhibitor from Medivir AB of Sweden. Ascletis acquired greater China rights for the antiviral, a NS5B inhibitor that has not yet started clinical trials. Ascletis' two other HCV treatments are in late-stage development, and the company hopes to market an all-oral, non-ribavirin combination HCV treatment in China soon. Ascletis made an upfront payment to Medivir and will pay milestones and royalties, though details of the agreement were not disclosed. More details....

Stock Symbol: (NSDQ: MVIR)



Share this with colleagues:





Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital